Pharmaceutical

European Commission greenlights Mirati’s Krazati in KRAS-mutated NSCLC 

Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.

Jan 11, 2024 - 18:00
European Commission greenlights Mirati’s Krazati in KRAS-mutated NSCLC 
Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.
Read the original article

Tags:

Previous Article

FDA approves import of French drug for syphilis amidst wider drug shortages

Next Article

Eli Lilly and Innovent’s obesity drug mazdutide achieves positive Phase III results

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market

STAT+: Pharmalittle: Bioscience job market is upside do...

Nov 27, 2023

Did the government get a bad deal on the Covid-19 boosters?

Did the government get a bad deal on the Covid-19 boost...

Sep 28, 2023

Santa Ana Bio secures $168m for inflammatory disease treatments

Santa Ana Bio secures $168m for inflammatory disease tr...

Jun 16, 2024